On Thursday 24 August 2017, the South African Tuberculosis Vaccine Initiative (SATVI) partnered with Ikamva Lethu, a women’s cooperative based in Worcester, in presenting a bead making workshop to learners at the Sinetemba Aftercare Centre in Zwelethemba, Worcester.
SATVI researcher Associate Professor Tom Scriba has co-authored a research paper titled: "The CSF Immune Response in HIV-1–Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy" appearing in the Journal of Acquired Immune Deficiency Syndrome.
South African Tuberculosis Vaccine Initiative (SATVI), located within Infectious Disease and Molecular Medicine (IDM) at the Faculty of Health Sciences invites applications from suitably qualified candidates for a 24-month contract position of Laboratory Technologist based in Worcester. CLOSED
SATVI authors have published research in which they find that the implementation of optimized procedures and a more rigorous QuantiFERON-TB conversion definition, an increase from IFNy<0.2 to >0.7 IU/mL, would allow more definitive detection of recent M.tb infection and potentially improve identification of those more likely to develop disease.
On Thursday 3 August the South African Tuberculosis Vaccine Initiative hosted a delegation from the Cape Winelands Education TB & HIV Program.
SATVI authors Professor Mark Hatherill, Associate Professor Tom Scriba, Drs. Munyaradzi Musvosvi and Virginie Rozoton have co-authored a research paper titled "Differential recognition of Mtb-specific epitopes as a function of tuberculosis disease history" appearing in the American Journal of Respiratory and Critical Care Medicine.
Welcome to Dr David M. Lewinsohn, visiting Professor of Pulmonary and Critical Care Medicine, who will be focusing on research into whether or not MR1-restricted T cells have the capacity for immunologic memory during his stay with SATVI.
SATVI authors Tom Scriba, Adam Penn-Nicholson and Mwandile Erasmus have co-authored a research paper titled "The Crosspecies Mycobacterial Growth Inhibition Assay (MGIA) Project 2010-2014" appearing in the Clinical and Vaccine Immunology journal.
SATVI authors have published an article titled “Impact of Isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination” appearing in the International Journal of Tuberculosis and Lung Disease.
Staff and students of the South African Tuberculosis Vaccine Initiative (SATVI) recently bid farewell to Doctor Hennie Geldenhuys, who will depart from SATVI at the end of June 2017.
Associate Professor Thomas Scriba has co-authored a research paper titled "Identifying specificity groups in the T cell receptor repertoire" appearing in the Nature Journal.
Researchers from the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Infectious Disease Research (CIDR) and Statens Serum Institute (SSI) have published research that provides important insights for determining which components of Mycobacterium tuberculosis should be included in TB vaccines as targets for the immune response.